Jean Xu

USPTO Granted Patents = 49 (Patent Applications = 11)

CIPO Patents = 13 (Patent Applications = 6)

EPO Patents = 23 (Patent Applications = 22)

Average Co-Inventor Count = 2.4

ph-index = 10

Forward Citations = 322(Granted Patents)

Location History:

Hillsborough, NJ (US) (2009 - 2015)
Warren, NJ (US) (2011 - 2023)
Skillman, NJ (US) (2014 - 2023)
Raritan, NJ (US) (2004 - 2024)

Company Filing History:

Janssen Biotech, Inc.

patents

8 out of 169

Signal Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

patents

7. 1 out of 1,036

The Cleveland Clinic Foundation

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441985 - Methods for making insulin in vivo (2025-10-14),

2. 12343346 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2025-07-01),

3. 11890304 - Pancreatic endocrine cells and methods thereof (2024-02-06),

4. 11708562 - Differentiation of human embryonic stem cells (2023-07-25),

5. 11629153 - Forms and compositions of a MK2 inhibitor (2023-04-18),

6. 11369642 - Methods for lowering blood glucose (2022-06-28),

7. 11241439 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2022-02-08),

8. 10882867 - Forms and compositions of a MK2 inhibitor (2021-01-05),

9. 10704025 - Use of noggin, an ALK5 inhibitor and a protein kinase c activator to produce endocrine cells (2020-07-07),

10. 10596180 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl) oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2020-03-24),

11. 10513519 - Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use (2019-12-24),

12. 10471104 - Lowering blood glucose (2019-11-12),

13. 10463672 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2019-11-05),

14. 10456424 - Pancreatic endocrine cells and methods thereof (2019-10-29),

15. 10202364 - Forms and compositions of an ERK inhibitor (2019-02-12),

Title: Innovations by Jean Xu: A Pioneer in MK2 Inhibition

Introduction

Jean Xu, based in Warren, NJ, is an accomplished inventor with an impressive portfolio of 28 patents. His work primarily focuses on the development of novel compounds with therapeutic applications. His innovative approach has contributed significantly to advancements in pharmacology and biochemistry.

Latest Patents

Among Jean Xu's latest inventions are two notable patents related to MK2 inhibitors. The first patent elaborates on solid forms and compositions of an MK2 inhibitor, providing methods for its utilization. The second patent presents salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, along with methods for their application and composition. These inventions highlight his commitment to creating effective therapeutic agents.

Career Highlights

Throughout his career, Jean Xu has made significant contributions while working at notable companies such as Celgene Corporation and Signal Pharmaceuticals, Inc. His innovative spirit and scientific rigor have propelled his research and development activities, leading to the successful patenting of numerous inventions.

Collaborations

Collaboration has been key in Jean's career. He has worked alongside prominent professionals, including Ying Li and Benjamin M. Cohen, fostering an environment of innovation and knowledge exchange. Together, they have been instrumental in advancing research and developing impactful solutions in the field.

Conclusion

Jean Xu stands out as a visionary inventor whose contributions to MK2 inhibitors offer promising therapeutic possibilities. His extensive number of patents and collaborative efforts underscore his role in the ongoing pursuit of scientific advancement. As he continues to innovate, the impact of his work on medicine and pharmacology is likely to grow significantly.

This text is generated by artificial intelligence and may not be accurate.